Loading...

The current price of MLTX is 14.32 USD — it has decreased -3.18 % in the last trading day.
MoonLake Immunotherapeutics, formerly known as Helix Acquisition Corp, is a Switzerland-based company engaged in the healthcare industry. The Firm is a clinical-stage biopharmaceutical company focused on the development of medicines for immunologic diseases, including inflammatory skin and joint diseases. The Company develops tri-specific nanobody Sonelokimab (SLK) which purpose is to target and penetrate difficult-to-reach inflamed tissues. SLK is a molecule with enhanced enrichment in deep skin & joints and binding of targets. SLK inhibits IL-17A and IL-17F inhibition to treat inflammatory diseases, by independently inhibiting the naturally-occurring IL-17 A/A, A/F and F/F dimers that drive inflammation in patients.
Wall Street analysts forecast MLTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MLTX is 15.38 USD with a low forecast of 5.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
MoonLake Immunotherapeutics revenue for the last quarter amounts to -71.43M USD, increased 65.69 % YoY.
MoonLake Immunotherapeutics. EPS for the last quarter amounts to -44543000.00 USD, increased 75.32 % YoY.
MoonLake Immunotherapeutics (MLTX) has 100 emplpoyees as of December 16 2025.
Today MLTX has the market capitalization of 1.03B USD.